Supernus Pharmaceuticals Inc (SUPN)
Working capital turnover
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 661,817 | 607,521 | 673,056 | 560,079 | 500,962 |
| Total current assets | US$ in thousands | 686,070 | 493,113 | 734,151 | 601,590 | 630,417 |
| Total current liabilities | US$ in thousands | 292,397 | 290,196 | 687,958 | 315,379 | 245,108 |
| Working capital turnover | 1.68 | 2.99 | 14.57 | 1.96 | 1.30 |
December 31, 2024 calculation
Working capital turnover = Revenue ÷ (Total current assets – Total current liabilities)
= $661,817K ÷ ($686,070K – $292,397K)
= 1.68
The working capital turnover ratio reflects how efficiently Supernus Pharmaceuticals Inc is utilizing its working capital to generate sales revenue.
Based on the provided data:
- As of December 31, 2020, the working capital turnover ratio was 1.30, indicating that for every $1 of working capital, the company generated $1.30 in sales.
- By December 31, 2021, the ratio improved to 1.96, suggesting better efficiency in utilizing working capital to drive sales growth.
- An exceptional surge in efficiency was observed by December 31, 2022, with a working capital turnover ratio of 14.57, signifying a significant increase in sales generated per unit of working capital.
- However, the ratio decreased to 2.99 by December 31, 2023, which could indicate a slowdown in sales relative to the working capital.
- By December 31, 2024, the ratio slightly declined to 1.68, still showing effective utilization of working capital to generate revenue.
In summary, while there were fluctuations over the years, Supernus Pharmaceuticals Inc generally demonstrated varying levels of efficiency in converting its working capital into sales revenue, with notable improvement in 2022 and fluctuations in subsequent years.
Peer comparison
Dec 31, 2024